EFFECT OF THE DRUG COATING CHARACTERISTICS ON VASCULAR REMODELING: COMPARING THE LATEST GENERATIONS OF STENTS

The basic method of myocardial revascularization in acute coronary syndrome is coronary stenting. Due to the high risk of later coronary events such as restenosis and late coronary thrombosis, studies on the different types of stents are currently underway.

The objective was to evaluate the degree of neointimal coverage of stents with a permanent and biodegradable polymer in one patient.

The patient with unstable angina was implanted 2 everolimus-containing stents with a constant polymer (Promus Premier) and a biodegradable polymer (Synergy). After 9 months, optical coherence tomography (OCT) was performed with the calculation of indicators.

774 struts of the Synergy and 701 struts of the Promus Premier were analyzed. When evaluating the thickness of the formed neointima, no significant differences was obtained (p=0.47). At the same time, a greater number of uncovered struts were detected in the Promus Premier stent compared with Synergy stent (1.14 vs. 0 %, p = 0.002). The number of malposed uncovered struts was not statistically different (0.14 versus 0.13, p = 1.00), the difference in the number of malposed struts covered approaches statistically significant (1.14 versus 0.26, p = 0.0545).

According to the results of optical coherence tomography, no significant differences between the studied platforms was obtained when assessing the late lumen loss. A greater number of uncovered struts in the stent with permanent polymer was detected, which could be considered as a risk factor for the development of late coronary thrombosis.

1. Demograficheskij ezhegodnik Rossii. 2017: stat. sb. Rosstat. Moscow, 2017:263. (In Russ.).

2. Chazov E. I., Boitsov S. A. Health care delivered to patients with acute coronary syndrome within the framework of the program on the setting up regional and primary vascular centers in the Russian Federation. Kardiologicheskij Vestnik. 2008;3(2):5–11. (In Russ.).

3. Kirtane A. J. et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009; 119(25):3198–3206.

4. Ahmed T. A. et al. Clinical performance of drug-eluting stents with biodegradable polymeric coating: a meta-analysis and systematic review. EuroIntervention. 2011;7(4):505–516.

5. Iakovou I. et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. Jama. 2005;293(17):2126–2130.

6. Soucy N. V. et al. Strut tissue coverage and endothelial cell coverage: a comparison between bare metal stent platforms and platinum chromium stents with and without everolimus-eluting coating. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2010;6(5):630–637.

7. Suwannasom P. et al. Evaluation of vascular healing of polymer-free sirolimus-eluting stents in native coronary artery stenosis: a serial follow-up at three and six months with optical coherence tomography imaging. EuroIntervention. 2016;12(5):e574–e583.

8. Ibragimov R. U. i dr. Sravnitel’nyj analiz endotelial’nogo pokrytiya everolimus-vydelyayushchih stentov Synergy s biodegradiruemym pokrytiem i Xience s postoyannym polimerom s pomoshch’yu opticheskoj kogerentnoj tomografii cherez 3 mesyaca posle chreskozhnogo koronarnogo vmeshatel’stva na stvole levoj koronarnoj arterii. Patologiya krovoobrashcheniya i kardiohirurgiya. 2017;21(4). (In Russ.). http://dx.doi.org/10.21688/1681-3472-2017-4-59-68.

9. Kim J. S. et al. Comparison of neointimal coverage of sirolimus-eluting stents and paclitaxel-eluting stents using optical coherence tomography at 9 months after implantation. Circulation Journal. 2010;74(2):320–326.

10. Kereiakes D. J. et al. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial. Circulation: Cardiovascular Interventions. 2015;8(4):e002372.

11. Kang S. H. et al. Stent thrombosis with drug-eluting stents and bioresorbable scaffolds: evidence from a network meta-analysis of 147 trials. JACC: Cardiovascular Interventions. 2016;9(12):1203–1212.

12. Neumann F. J. et al. 2018 ESC/EACTS guidelines on myocardial revascularization. European heart journal. 2018; 40(2):87–165.

13. Dygaj A. M. K voprosu ob antiproliferativnom pokrytii koronarnyh stentov. Patologiya krovoobrashcheniya i kardiohirurgiya. 2018;22(2). (In Russ.).